About: Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
Creator	Reiter, Russel Es, Escames, Germaine Feder, Francisco López-Muñoz, · Gil-Martín, Emilio Iii, Carlos Ramos, Eva Romero, Alejandro
Source	Medline; PMC
abstract	The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.
has issue date	2020-08-09(xsd:dateTime)
bibo:doi	10.1007/s10571-020-00938-8
bibo:pmid	32772307
has license	no-cc
sha1sum (hex)	5d8c09e4d7b33c68c96b4d163658eaa45b5b5739
schema:url	https://doi.org/10.1007/s10571-020-00938-8
resource representing a document's title	Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
has PubMed Central identifier	PMC7415199
has PubMed identifier	32772307
schema:publication	Cell Mol Neurobiol
resource representing a document's body	covid:5d8c09e4d7b33c68c96b4d163658eaa45b5b5739#body_text
is schema:about of	named entity 'cerebrospinal fluid' named entity 'COVID-19' named entity 'receptor' named entity 'CaMKII' named entity '2019' named entity 'NEW' named entity 'DISCUSS' named entity 'SPREADS' covid:arg/5d8c09e4d7b33c68c96b4d163658eaa45b5b5739 named entity 'prevention' named entity 'modulate' named entity 'caused' named entity 'SARS-CoV-2' named entity 'postmortem examination' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'neuroinvasion' named entity 'hippocampal' named entity 'ACE2' named entity 'innate immune responses' named entity 'dimerize' named entity 'Melatonin receptor' named entity 'sore throat' named entity 'COVID-19.' named entity 'reveals' named entity 'melatonin' named entity 'CSF' named entity 'patients' named entity 'neuroinflammation' named entity 'Angiotensin-converting enzyme 2' named entity 'nicotinic receptor' named entity 'coronavirus disease 2019' named entity 'virus' named entity 'World Health Organization' named entity 'neuroinflammation' named entity 'COVID-19' named entity 'central nervous' named entity 'COVID-19 outbreak' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'ACE2' named entity 'COVID-19' named entity 'Coronavirus Disease 2019' named entity 'CaMKII' named entity 'Angiotensin-converting enzyme 2' named entity 'Calmodulin' named entity 'acetylcholine' named entity 'Melatonin' named entity 'receptor' named entity 'COVID-19' named entity 'life-threatening' named entity 'cytosol' named entity 'COVID-19' named entity 'olfactory bulb' named entity 'therapeutic strategies' named entity 'antiviral' named entity 'mitochondrial function' named entity 'COVID' named entity 'Wuhan' named entity 'SARS-CoV-2' named entity 'mTOR' named entity 'ACE2' named entity 'pro-inflammatory' named entity 'neurotransmission' named entity 'serotonin' named entity 'immune response' named entity 'protease' named entity 'Nataf' named entity 'CaM' named entity 'melatonin' named entity 'cytokine storm syndrome' named entity 'HLH' named entity 'organelles'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software